GET DAILY SIGNALSWalmart (WMT$146.53) earnings forecast on February 21
On Tuesday, February 21, Walmart will be announcing its earnings forecast for the upcoming year. This is a highly anticipated event, as Walmart is one of the largest retailers in the world, and its performance often reflects broader trends in the global economy.
Walmart's most recent earnings report, released in November 2022, showed strong growth in e-commerce sales, which increased by 43% compared to the same quarter the previous year. However, the company also reported slower growth in physical store sales, with a 1.9% increase compared to the same quarter the previous year.
Investors will be looking closely at Walmart's earnings forecast to see how the company expects to perform in the coming year. With the ongoing COVID-19 pandemic continuing to impact the retail industry, it's likely that Walmart's e-commerce sales will remain strong, as consumers continue to do more of their shopping online. However, the company may continue to struggle with growth in physical stores, particularly as the pandemic has led to changes in consumer behavior.
Overall, Walmart's earnings forecast will be an important indicator of the health of the retail industry, as well as broader trends in the global economy. Investors and analysts will be paying close attention to the company's performance, looking for signs of continued growth and adaptation to the changing retail landscape.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CVS sees MACD Histogram crosses below signal line
CVS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 51 instances where the indicator turned negative. In 33 of the 51 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 65%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 51 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.
CVS moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CVS crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CVS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 228 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
CVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 163 of 253 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.305) is slightly lower than the industry average of (3.512). P/E Ratio (21.291) is within average values for comparable stocks, (126.100). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS's Dividend Yield (0.033) is considerably higher than the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement